Larimar Therapeutics, Inc. (LRMR)
Stock Price:
$21.72 USD
0.81 (3.87%)
Updated November 27, 1:00 PM EST - Market closed
Key Info
| Market Cap |
333.54M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-32.45M |
| Shares Out |
15.36M |
| EPS (ttm) |
-5.45 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
November 27 |
| Last Price |
$21.72 |
| Previous Close |
$20.91 |
| Change ($) |
0.81 |
| Change (%) |
3.87% |
| Day's Open |
20.91 |
| Day's Range |
20.91 - 21.99 |
| Day's Volume |
20,608 |
| 52-Week Range |
7.43 - 23.72 |
More Stats
| Market Cap |
333.54M |
| Enterprise Value |
236.55M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
15.36M |
| Float |
13.93M |
| EPS (basic) |
-5.45 |
| EPS (diluted) |
-5.45 |
| FCF / Share |
-2.66 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
102,598 |
| Short Ratio |
2.74 |
| Short % of Float |
0.74% |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
3.25 |
| Revenue |
n/a |
| Operating Income |
-32.58M |
| Net Income |
-32.45M |
| Free Cash Flow |
-42.50M |
| Net Cash |
96.99M |
| Net Cash / Share |
6.32 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-280.42% |
| ROE |
n/a |
| ROIC |
-189.40% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Low
9.36
Current: $21.72
High
9.36
Target: 9.36
*Average 12-month price target from 1 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|
| Revenue | - | - | - | - | - | - | - | - | - |
| Operating Income | -45.65 | -61.12 | -53.00 | -58.23 | -73.81 | -35.53 | -13.78 | -13.79 | -13.15 |
| Net Income | -45.41 | -61.37 | -52.03 | -57.88 | -74.29 | -36.48 | -14.03 | -13.88 | -13.16 |
| Shares Outstanding | 3.11 | 2.69 | 2.29 | 2.27 | 2.23 | 1.02 | 0.06 | 0.06 | 0.06 |
| Earnings Per Share | -14.64 | -22.80 | -22.80 | -25.44 | -33.36 | -36.00 | -234.37 | -235.81 | -230.05 |
| Operating Cash Flow | -40.78 | -51.49 | -43.78 | -51.98 | -59.55 | -28.24 | -15.00 | -13.59 | -12.27 |
| Capital Expenditures | -1.35 | -0.11 | -0.06 | -0.66 | -0.60 | -0.06 | -0.02 | - | -0.03 |
| Free Cash Flow | -42.13 | -51.60 | -43.84 | -52.64 | -60.15 | -28.30 | -15.02 | -13.59 | -12.31 |
| Cash & Equivalents | 1.01 | 118 | 102 | 129 | 185 | 115 | 35.52 | 9.94 | - |
| Total Debt | 0.10 | 20.64 | 20.00 | 3.59 | 6.39 | 7.56 | - | - | - |
| Net Cash / Debt | 0.91 | 97.43 | 82.05 | 126 | 179 | 108 | 35.52 | 9.94 | - |
| Assets | 5.20 | 122 | 106 | 132 | 189 | 118 | 38.14 | 10.99 | - |
| Liabilities | 5.90 | 28.49 | 27.29 | 9.89 | 20.00 | 13.08 | 2.92 | 2.93 | - |
| Book Value | -0.69 | 93.27 | 78.22 | 122 | 169 | 104 | -68.57 | -54.73 | - |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Larimar Therapeutics, Inc. |
| Country |
United States |
| Employees |
16 |
| CEO |
Carole S. Ben-Maimon |
Stock Information
| Ticker Symbol |
LRMR |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: LRMR |
Description
Larimar Therapeutics, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases. The company's lead compound is CTI-1601, a Phase 1 clinical program to treat Friedreich's ataxia, a rare and progressive genetic disease. The company is headquartered in Bala Cynwyd, Pennsylvania.